Vantage Consulting Group Inc Incyte Corp Transaction History

Vantage Consulting Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $10,287 - $12,813	-201 Reduced 5.08%	3,757 $227,000
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $18,209 - $21,441	-322 Reduced 7.52%	3,958 $225,000
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $34,373 - $42,301	659 Added 18.2%	4,280 $268,000
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $8,954 - $10,219	-155 Reduced 4.1%	3,621 $209,000
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $27,305 - $33,828	448 Added 13.46%	3,776 $235,000
Q1 2023 May 10, 2023	BUY	$70.23 - $86.01 $27,600 - $33,801	393 Added 13.39%	3,328 $240,000
Q4 2022 Feb 13, 2023	SELL	$67.18 - $84.11 $42,054 - $52,652	-626 Reduced 17.58%	2,935 $235,000
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $9,927 - $12,429	150 Added 4.4%	3,561 $237,000
Q2 2022 Aug 09, 2022	BUY	$66.18 - $83.18 $20,184 - $25,369	305 Added 9.82%	3,411 $259,000
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $57,635 - $69,586	-873 Reduced 21.94%	3,106 $247,000
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $34,520 - $40,389	545 Added 15.87%	3,979 $292,000
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $46,420 - $56,797	676 Added 24.51%	3,434 $236,000
Q2 2021 Aug 11, 2021	BUY	$79.87 - $87.53 $220,281 - $241,407	2,758 New	2,758 $232,000
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $68,189 - $90,148	-897 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $72,423 - $87,636	897 New	897 $78,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vantage Consulting Group Inc with notifications on news.